Swine Flu: 'the next time someone cries wolf on a pandemic, it will not be taken seriously'

31 March 2010

"The next time someone cries wolf over a pandemic, the overwhelming majority will not take it seriously,' participants were told this week at a parliamentary hearing on the handling of the H1N1 pandemic, organized in Paris, France, by the Parliamentary Assembly of the Council of Europe (PACE) Social, Health and Family Affairs Committee.

The meeting was in response to criticism of the World Health Organization's handling of the H1N1 influenza pandemic, and alleged influence of the pharmaceutical industry in causing the situation, and follows a public hearing by the PACE committee in January (The Pharma Letters passim).

'A pandemic cannot be whatever the WHO declares it is. If it turns out that former PACE member Wolfgang Wodarg was right when he said the pandemic was decided to help the pharmaceutical industry make bigger profits, this might well turn out to be one of the biggest health scandals ever,' said Paul Flynn (UK, SOC), PACE rapporteur on this issue.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical